|Company name||Intercept Pharmaceuticals, Inc.|
|Class period||May 31, 2016 – September 20, 2017|
|Lead plaintiff deadline||November 27, 2017|
|Court||Southern District of New York|
NEW YORK, October 11, 2017 – Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) securities between May 31, 2016 and September 20, 2017 (the “Class Period”). Investors have until November 27, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the Complaint, throughout the Class Period, Intercept made materially false and/or misleading statements and/or failed to disclose that its lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis (“PBC”). As a result, the Company’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been connected to liver injuries and death among patients suffering from PBC. On September 21, 2017, the U.S. Food & Drug Administration issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” warning doctors after reports of multiple deaths linked to the drug. Following this news, shares of Intercept fell in value materially, which caused investors harm according to the Complaint.
If you purchased or otherwise acquired Intercept securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.